 | • レポートコード：MRC2304D099 • 出版社/出版日：Transparency Market Research / 2023年1月5日 • レポート形態：英文、PDF、233ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、輸液療法の世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、製品別（輸液ポンプ、輸液セット、付属品）分析、疾患別（がん、消化器疾患＆障害、うっ血性心不全、関節リウマチ、その他）分析、治療種類別（抗生物質/抗ウイルス、抗凝固、制吐薬、血液成分刺激因子、その他）分析、エンドユーザー別（病院、外来手術センター、クリニック、在宅医療）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを収録しています。また、B. Braun Melsungen AG、Medtronic plc、Becton, Dickinson and Company、ICU medical (Smiths Medical)、Baxter International, Inc.、Polymedicure、BIO-MED、Terumo Medical Corporation、MEDIPRIM GmbH、Fresenius Kabi、Cardinal Healthなどの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の輸液療法市場規模：製品別（輸液ポンプ、輸液セット、付属品）分析、疾患別（がん、消化器疾患＆障害、うっ血性心不全、関節リウマチ、その他）分析、治療種類別（抗生物質/抗ウイルス、抗凝固、制吐薬、血液成分刺激因子、その他）分析、エンドユーザー別（病院、外来手術センター、クリニック、在宅医療）分析、 - 輸液ポンプの市場規模 - 輸液セットの市場規模 - 付属品の市場規模 ・世界の輸液療法市場規模：疾患別 - がんにおける市場規模 - 消化器疾患＆障害における市場規模 - うっ血性心不全における市場規模 - 関節リウマチにおける市場規模 - その他疾患における市場規模 ・世界の輸液療法市場規模：治療種類別 - 抗生物質/抗ウイルス治療の市場規模 - 抗凝固の市場規模 - 制吐薬の市場規模 - 血液成分刺激因子治療の市場規模 - その他治療種類の市場規模 ・世界の輸液療法市場規模：エンドユーザー別 - 病院における市場規模 - 外来手術センターにおける市場規模 - クリニックにおける市場規模 - 在宅医療における市場規模 ・世界の輸液療法市場規模：地域別 - 北米の輸液療法市場規模 - ヨーロッパの輸液療法市場規模 - アジア太平洋の輸液療法市場規模 - 中南米のアルミニウムスラグ市場規模 - 中東・アフリカのアルミニウムスラグ市場規模 ・競争状況 |
Infusion Therapy Market – Scope of Report
TMR’s report on the global infusion therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global infusion therapy market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global infusion therapy market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the infusion therapy market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global infusion therapy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global infusion therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global infusion therapy market.
The report delves into the competitive landscape of the global infusion therapy market. Key players operating in the global infusion therapy market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global infusion therapy market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market infusion therapy.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Infusion Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Porter’s Five Force Analysis
5. Key Insights
5.1. Key Industry Developments
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Technological Advancements
5.4. Regulatory Scenario by Region/globally
5.5. Covid-19 Pandemic impact on the industry
6. Global Infusion Therapy Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Infusion Pumps
6.3.1.1. Ambulatory Infusion Pumps
6.3.1.2. Stationary Infusion Pumps
6.3.1.3. Syringe Infusion Pumps
6.3.1.4. Disposable Pumps
6.3.1.5. Large Volume Pumps
6.3.1.6. Elastomeric Pumps
6.3.2. Infusion Set
6.3.3. Accessories
6.4. Market Attractiveness Analysis, by Product
7. Global Infusion Therapy Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Cancer
7.3.2. Gastrointestinal Diseases / Disorders
7.3.3. Congestive Heart Failure
7.3.4. Rheumatoid Arthritis
7.3.5. Hemophilia
7.3.6. Immune Deficiencies
7.3.7. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Infusion Therapy Market Analysis and Forecast, by Therapy Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Therapy Type, 2017–2031
8.3.1. Antibiotic/Antiviral
8.3.2. Anti-coagulation
8.3.3. Anti-emetics
8.3.4. Blood Component Stimulating Factor
8.3.5. Chemotherapy
8.3.6. Nutrition
8.3.7. Hydration
8.3.8. Pain Management
8.4. Market Attractiveness Analysis, by Therapy Type
9. Global Infusion Therapy Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Clinics
9.3.4. Homecare Settings
9.4. Market Attractiveness Analysis, by End-user
10. Global Infusion Therapy Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Infusion Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Infusion Pumps
11.2.1.1. Ambulatory Infusion Pumps
11.2.1.2. Stationary Infusion Pumps
11.2.1.3. Syringe Infusion Pumps
11.2.1.4. Disposable Pumps
11.2.1.5. Large Volume Pumps
11.2.1.6. Elastomeric Pumps
11.2.2. Infusion Set
11.2.3. Accessories
11.3. Market Value Forecast, by Indication, 2017–2031
11.3.1. Cancer
11.3.2. Gastrointestinal Diseases / Disorders
11.3.3. Congestive Heart Failure
11.3.4. Rheumatoid Arthritis
11.3.5. Hemophilia
11.3.6. Immune Deficiencies
11.3.7. Others
11.4. Market Value Forecast, by Therapy Type, 2017–2031
11.4.1. Antibiotic/Antiviral
11.4.2. Anti-coagulation
11.4.3. Anti-emetics
11.4.4. Blood Component Stimulating Factor
11.4.5. Chemotherapy
11.4.6. Nutrition
11.4.7. Hydration
11.4.8. Pain Management
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Ambulatory Surgical Centers
11.5.3. Clinics
11.5.4. Homecare Settings
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Indication
11.7.3. By Therapy Type
11.7.4. By End-user
11.7.5. By Country
12. Europe Infusion Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Infusion Pumps
12.2.1.1. Ambulatory Infusion Pumps
12.2.1.2. Stationary Infusion Pumps
12.2.1.3. Syringe Infusion Pumps
12.2.1.4. Disposable Pumps
12.2.1.5. Large Volume Pumps
12.2.1.6. Elastomeric Pumps
12.2.2. Infusion Set
12.2.3. Accessories
12.3. Market Value Forecast, by Indication, 2017–2031
12.3.1. Cancer
12.3.2. Gastrointestinal Diseases / Disorders
12.3.3. Congestive Heart Failure
12.3.4. Rheumatoid Arthritis
12.3.5. Hemophilia
12.3.6. Immune Deficiencies
12.3.7. Others
12.4. Market Value Forecast, by Therapy Type, 2017–2031
12.4.1. Antibiotic/Antiviral
12.4.2. Anti-coagulation
12.4.3. Anti-emetics
12.4.4. Blood Component Stimulating Factor
12.4.5. Chemotherapy
12.4.6. Nutrition
12.4.7. Hydration
12.4.8. Pain Management
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Ambulatory Surgical Centers
12.5.3. Clinics
12.5.4. Homecare Settings
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Indication
12.7.3. By Therapy Type
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Infusion Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Infusion Pumps
13.2.1.1. Ambulatory Infusion Pumps
13.2.1.2. Stationary Infusion Pumps
13.2.1.3. Syringe Infusion Pumps
13.2.1.4. Disposable Pumps
13.2.1.5. Large Volume Pumps
13.2.1.6. Elastomeric Pumps
13.2.2. Infusion Set
13.2.3. Accessories
13.3. Market Value Forecast, by Indication, 2017–2031
13.3.1. Cancer
13.3.2. Gastrointestinal Diseases / Disorders
13.3.3. Congestive Heart Failure
13.3.4. Rheumatoid Arthritis
13.3.5. Hemophilia
13.3.6. Immune Deficiencies
13.3.7. Others
13.4. Market Value Forecast, by Therapy Type, 2017–2031
13.4.1. Antibiotic/Antiviral
13.4.2. Anti-coagulation
13.4.3. Anti-emetics
13.4.4. Blood Component Stimulating Factor
13.4.5. Chemotherapy
13.4.6. Nutrition
13.4.7. Hydration
13.4.8. Pain Management
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Ambulatory Surgical Centers
13.5.3. Clinics
13.5.4. Homecare Settings
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Indication
13.7.3. By Therapy Type
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Infusion Therapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Infusion Pumps
14.2.1.1. Ambulatory Infusion Pumps
14.2.1.2. Stationary Infusion Pumps
14.2.1.3. Syringe Infusion Pumps
14.2.1.4. Disposable Pumps
14.2.1.5. Large Volume Pumps
14.2.1.6. Elastomeric Pumps
14.2.2. Infusion Set
14.2.3. Accessories
14.3. Market Value Forecast, by Indication, 2017–2031
14.3.1. Cancer
14.3.2. Gastrointestinal Diseases / Disorders
14.3.3. Congestive Heart Failure
14.3.4. Rheumatoid Arthritis
14.3.5. Hemophilia
14.3.6. Immune Deficiencies
14.3.7. Others
14.4. Market Value Forecast, by Therapy Type, 2017–2031
14.4.1. Antibiotic/Antiviral
14.4.2. Anti-coagulation
14.4.3. Anti-emetics
14.4.4. Blood Component Stimulating Factor
14.4.5. Chemotherapy
14.4.6. Nutrition
14.4.7. Hydration
14.4.8. Pain Management
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Ambulatory Surgical Centers
14.5.3. Clinics
14.5.4. Homecare Settings
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Indication
14.7.3. By Therapy Type
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Infusion Therapy Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Infusion Pumps
15.2.1.1. Ambulatory Infusion Pumps
15.2.1.2. Stationary Infusion Pumps
15.2.1.3. Syringe Infusion Pumps
15.2.1.4. Disposable Pumps
15.2.1.5. Large Volume Pumps
15.2.1.6. Elastomeric Pumps
15.2.2. Infusion Set
15.2.3. Accessories
15.3. Market Value Forecast, by Indication, 2017–2031
15.3.1. Cancer
15.3.2. Gastrointestinal Diseases / Disorders
15.3.3. Congestive Heart Failure
15.3.4. Rheumatoid Arthritis
15.3.5. Hemophilia
15.3.6. Immune Deficiencies
15.3.7. Others
15.4. Market Value Forecast, by Therapy Type, 2017–2031
15.4.1. Antibiotic/Antiviral
15.4.2. Anti-coagulation
15.4.3. Anti-emetics
15.4.4. Blood Component Stimulating Factor
15.4.5. Chemotherapy
15.4.6. Nutrition
15.4.7. Hydration
15.4.8. Pain Management
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Ambulatory Surgical Centers
15.5.3. Clinics
15.5.4. Homecare Settings
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Indication
15.7.3. By Therapy Type
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. B. Braun Melsungen AG
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Medtronic plc
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Becton, Dickinson and Company
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. ICU medical (Smiths Medical)
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Baxter International, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Polymedicure
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. BIO-MED
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Terumo Medical Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. MEDIPRIM GmbH
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Fresenius Kabi
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Cardinal Health
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview